{
  "docId": "019de073-4386-7700-b700-92166fcbcd7c",
  "docSlug": "fd316ea801ff13186537922fd8d6b6b2",
  "documentTitle": "BioNTech | Investor Presentation Deck | 28 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 28,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "product_demo",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a matrix structure to compare different drug development programs.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-4386-7700-b700-92166fcbcd7c/24",
  "deckHref": "/decks/019de073-4386-7700-b700-92166fcbcd7c",
  "deckJsonHref": "/decks/019de073-4386-7700-b700-92166fcbcd7c.json",
  "deckAnchorHref": "/decks/019de073-4386-7700-b700-92166fcbcd7c#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.65,
        "x": 0.09,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "R/R, refractory/relapsed; HPV16+, human papilloma virus type 16 positive; HNSCC, head and neck squamous cell carcinoma; NK cell, natural killer cell; CPI, checkpoint inhibitor. 1 Collaboration with Genentech, 2 Collaboration with Genmab.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f1dbd807-4626-4cf7-8645-04ac6d86e33c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.92,
        "x": 0.04,
        "y": 0.19
      },
      "kind": "table",
      "text": "Matrix of platforms (FixVac, iNeST, Bispecific) vs program details (Program, How, Why)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ac58ca6-da4c-42a5-84ad-906d43f80e0c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.35,
        "x": 0.04,
        "y": 0.09
      },
      "kind": "title",
      "text": "Oncology Programs in Phase 2",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76afdd12-b90f-4dc6-a434-118879d1e804",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "373144c4-464d-45e7-a014-e3bc47d28488",
      "evidence": "The slide contains a table/matrix with data on the company's oncology programs in Phase 2.",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "matrix-nxn",
      "slug": null,
      "matchId": "a9b502f5-2e4b-4175-b8f7-16be8a13ab07",
      "evidence": "The slide organizes information in a grid comparing platforms against program attributes.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 24,
      "from": 19,
      "beatId": "24f1c7cb-ed51-471a-8d42-de7584f2b8af",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "Infectious Diseases and Oncology slides showcase product pipeline",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 28,
      "from": 6,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "3cf6d9b3-9631-47e6-918d-3327cacea976",
      "evidence": "The presentation follows a 'why-what-how' structure",
      "position": 0,
      "objective": "Why BioNTech's approach is necessary and beneficial",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}